USFDA completes inspection of Biocon Bengaluru plant with no observations
Zero Observation
The audit concluded without any observations and no Form 483 was issued, the company added.
A Form 483, is issued by the USFDA to notify a company's management of any objectionable conditions at its manufacturing facilities. It is issued to the management of a firm at the conclusion of an inspection.
New Delhi: Biotechnology major Biocon has announced the US health regulator has completed the inspection of its new manufacturing facility in Bengaluru without any observations. "The United States Food and Drug Administration(USFDA) conducted a pre-approval inspection of our new oral solid dosage forms manufacturing facility at Biocon Park in Bengaluru from November 5-9, 2018," Biocon said in a regulatory filing.
The audit concluded without any observations and no Form 483 was issued, the company added.
A Form 483, is issued by the USFDA to notify a company's management of any objectionable conditions at its manufacturing facilities. It is issued to the management of a firm at the conclusion of an inspection.
Read Also: USFDA completes inspection of Biocon drug substance unit at Bengaluru
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd